清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

医学 临床试验 内科学 肿瘤科 临床终点 人口 耐火材料(行星科学) 外科 天体生物学 环境卫生 物理
作者
Roelof van Ewijk,Morgane Cleirec,Nikolas Herold,Marie-Cécile Le Deley,Natasha van Eijkelenburg,Pascaline Boudou‐Rouquette,Severine Risbourg,Sandra J. Strauss,Emanuela Palmerini,Kjetil Boye,Leo Kager,Stefanie Hecker‐Nolting,Antonin Marchais,Nathalie Gaspar
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:120: 102625-102625
标识
DOI:10.1016/j.ctrv.2023.102625
摘要

Background/ObjectiveTo analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis.MethodsA systematic review of trials registered on trial registries between 01/01/2017–14/02/2022. Comparison of 98 trials identified between 2003 and 2016. Publication search/analysis for both periods, last update on 01/12/2022.ResultsBetween 2017 and 2022, 71 phase-II trials met our selection criteria (19 osteosarcoma-specific trials, 14 solid tumor trials with and 38 trials without an osteosarcoma-specific stratum). The trial number increased over time: 13.9 versus 7 trials/year (p = 0.06). Monotherapy remained the predominant treatment (62% vs. 62%, p = 1). Targeted therapies were increasingly evaluated (66% vs. 41%, P = 0.001). Heterogeneity persisted in the trial characteristics. The inclusion criteria were measurable disease (75%), evaluable disease (14%), and surgical remission (11%). 82% of the trials included pediatric or adolescent patients. Biomarker-driven trials accounted for 25% of the total trials. The survival endpoint use (rather than response) slightly increased (40% versus 31%), but the study H1/H0 hypotheses remained heterogeneous. Single-arm designs predominated over multiarm trials (n = 7). Available efficacy data on 1361 osteosarcoma patients in 58 trials remained disappointing, even though 21% of these trials were considered positive, predominantly those evaluating multi-targeted kinase inhibitors.ConclusionDespite observed changes in trial design and an increased number of trials investigating new therapies, high heterogeneity remained with respect to patient selection, study design, primary endpoints, and statistical hypotheses in recently registered phase II trials for osteosarcoma. Continued optimization of trial design informed by a deeper biological understanding should strengthen the development of new therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FashionBoy应助康康XY采纳,获得30
9秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
14秒前
蓝天阳光完成签到,获得积分10
21秒前
23秒前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
科研通AI2S应助chenqi采纳,获得10
1分钟前
1分钟前
白天亮完成签到,获得积分10
1分钟前
完美世界应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
Owen应助科研通管家采纳,获得10
2分钟前
Owen应助科研通管家采纳,获得10
2分钟前
Glitter完成签到 ,获得积分10
2分钟前
00完成签到 ,获得积分10
2分钟前
量子星尘发布了新的文献求助10
3分钟前
3分钟前
康康XY发布了新的文献求助30
3分钟前
3分钟前
3分钟前
研友_8y2G0L完成签到,获得积分10
4分钟前
mathmotive完成签到,获得积分20
4分钟前
双手外科结完成签到,获得积分10
4分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
4分钟前
梵莫发布了新的文献求助10
4分钟前
4分钟前
nojego完成签到,获得积分10
4分钟前
5分钟前
量子星尘发布了新的文献求助10
5分钟前
5分钟前
6分钟前
梵莫发布了新的文献求助10
6分钟前
深情安青应助科研通管家采纳,获得10
6分钟前
6分钟前
量子星尘发布了新的文献求助10
6分钟前
CodeCraft应助康康XY采纳,获得10
6分钟前
无一完成签到 ,获得积分0
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Immigrant Incorporation in East Asian Democracies 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3972811
求助须知:如何正确求助?哪些是违规求助? 3517116
关于积分的说明 11186225
捐赠科研通 3252713
什么是DOI,文献DOI怎么找? 1796589
邀请新用户注册赠送积分活动 876487
科研通“疑难数据库(出版商)”最低求助积分说明 805701